UAE to test the effectiveness of CAR T-cell therapy for treating blood cancers
A research institute in Abu Dhabi will become the first in the region to locally manufacture and test the safety and effectiveness of immunotherapy for treating blood cancers, such as myeloma, lymphoma and certain forms of leukemia.
Abu Dhabi Stem Cells Centre (ADSCC) on Thursday announced that chimeric antigen receptor (CAR) T-cell therapy represents a new, internationally recognized form of immunotherapy.
CAR T-cell therapy harnesses the body’s defense system by reprogramming T-cells, a crucial component in the body’s anti-tumor response, to go on search-and-destroy missions to kill cancer.
These reprogrammed cells become a living drug that mobilizes through the body, continually tapping the immune system to attack disease.